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LysosomePodocyte apoptosis is a potent mechanism of proteinuria in diabetic nephropathy. More detailedmechanistic in-
sight into podocyte apoptosis is needed to better understand the pathogenesis of diabetic nephropathy. An ele-
vated level of serum free fatty acid (FFA), aswell as hyperglycemia, is a clinical characteristic in diabetes, although
its causal role in podocyte apoptosis remains unclear. This study examined the effect of three types of FFAs, sat-
urated, monounsaturated and polyunsaturated FFAs, on podocyte apoptosis. Palmitate, a saturated FFA, induced
endoplasmic reticulum (ER) stress-dependent apoptosis in podocytes. Oleate, a monounsaturated FFA, and
eicosapentaenoic acid (EPA), an ω− 3 polyunsaturated FFA did not induce apoptosis; rather, they antagonized
palmitate-induced apoptosis. Palmitate activated mammalian target of rapamycin (mTOR) complex 1
(mTORC1), a nutrient-sensing kinase regulating a wide range of cell biology. Furthermore, inhibition of
mTORC1 activity by rapamycin or siRNA for Raptor, a component of mTORC1, ameliorated palmitate-induced
ER stress and apoptosis in podocytes. Activity of mTORC1 is regulated by upstream kinases and Rag/Ragulator-
dependent recruitment ofmTOR onto lysosomal membranes. Palmitate activatedmTORC1 by enhancing recruit-
ment of mTOR onto lysosomal membranes, which was inhibited by co-incubation with oleate or EPA. Inhibition
of mTOR translocation onto lysosomes by transfection with dominant-negative forms of Rag ameliorated
palmitate-induced apoptosis. This study suggests that saturated and unsaturated FFAs have opposite effects on
podocyte apoptosis by regulating mTORC1 activity via its translocation onto lysosomal membranes, and the re-
sults provide a better understanding of the pathogenesis in diabetic nephropathy and a novel role of mTORC1
in cell apoptosis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Diabetic nephropathy is a leading cause of end-stage renal disease
and is a serious health problemworldwide. Proteinuria is amajor aspect
of diabetic nephropathy and is caused by disruption to the glomerular
ﬁltration barrier [1]. Glomerular epithelial cells (podocytes) are potentCHOP, C/EBP homologous pro-
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e).component cells that maintain glomerular ﬁltration barrier function.
Podocyte loss by apoptosis is a main cause of proteinuria in diabetic ne-
phropathy [1,2], since podocytes are highly specialized, terminally dif-
ferentiated and unable to proliferate. Protecting podocytes against
apoptosis has therefore become a principal therapeutic target for dia-
betic nephropathy. However, detailedmechanisms of podocyte apopto-
sis in diabetes have not been fully elucidated.
Insufﬁciency of insulin action to skeletal muscle and the liver leads
to hyperglycemia [3,4], which strongly associates with both the onset
and progression of diabetic vascular complications [5–8]. As well as hy-
perglycemia, higher levels of serum free fatty acids (FFAs) resulting
from insufﬁcient insulin action to white adipose tissue have recently
been suggested as a novel cause of organ dysfunction in diabetes
[9–12]. Serum FFAs are composed of saturated fatty acids, monounsatu-
rated fatty acids and polyunsaturated fatty acids. The composition is
modiﬁed by altered metabolic states, such as obesity and diabetes
[13–15]. In addition to high levels of serum FFAs, modiﬁed FFA
1098 M. Yasuda et al. / Biochimica et Biophysica Acta 1842 (2014) 1097–1108composition has recently been the focus of study as they may be an ad-
ditional causal factor of diabetes-related diseases [16–18]. However, the
role of modiﬁed FFA composition in diabetes-related podocyte apopto-
sis remains unclear.
Mammalian target of rapamycin (mTOR) is an evolutionarily con-
served protein kinase and forms two functional complexes, termed
mTOR complex (mTORC) 1 and mTORC2 [19]. mTORC1 is a rapamycin-
sensitive protein kinase complex of six proteins, including Raptor, that
regulates a wide array of cellular processes including cell growth, prolif-
eration and autophagy [19,20]. Some nutrient-relatedmolecules, such as
insulin, glucose and amino acids, activate mTORC1; although each regu-
latory mechanism is different. mTORC1 is ﬁnally activated by a small
GTPase, the Ras homolog enriched in brain (Rheb), that is anchored to ly-
sosomal membranes [21]. Insulin activates mTORC1 via Akt-dependent
inactivation of tuberous sclerosis complex 1/2 (TSC1/2), a suppressor of
Rheb [20,22,23]. A high glucose condition activates mTORC1 via inhibi-
tion of AMP-activated protein kinase (AMPK), an activator of TSC1/2
and a direct suppressor of Raptor [24]. Unlike these mechanisms,
amino acids, glucose and glutaminolysis enhance translocation of
mTORC1 onto lysosomal membranes in a Rag–Ragulator complex-
dependent manner, leading to mTORC1 activation [25–29]. mTORC1
can act as a nutrient-sensing kinase regulating cellular processes; how-
ever, the relationship between FFA, a nutrient, and mTORC1 has not
been fully elucidated.
Hyperactivation of mTORC1 is likely to be associated with the path-
ogenesis of various diabetes- and age-related diseases [30–32]. Growing
evidence suggests that mTORC1 is pathologically activated in podocytes
of the diabetic kidney in both humans and rodent models, and inactiva-
tion of mTORC1 ameliorated podocyte injury in diabetic nephropathy
[33,34]. mTORC1 inhibition has recently been suggested as a new ther-
apeutic target to prevent diabetic nephropathy [35–37]. However, it is
also likely that very strong inhibition of mTORC1 causes podocyte dys-
function leading to proteinuria, suggesting that a basal level of
mTORC1 activity is required for maintaining the basic physiology of
podocytes [38–40]. Therefore, more detailed mechanisms of diabetes-
related hyperactivation ofmTORC1 are required to establish an effective
and safe therapy that targets mTORC1 inhibition.
We hypothesized that composite changes in serum FFAs contribute
to diabetes-related mTORC1 hyperactivity, leading to podocyte apopto-
sis in diabetic nephropathy. To test this hypothesis, we examined the ef-
fect of each kind of FFA (saturated, monounsaturated and ω − 3
polyunsaturated fatty acids) on mTORC1 activation and apoptosis in
cultured podocytes. The results suggest that FFAs are potent nutrients
regulating the pro-apoptotic function of mTORC1 in podocytes.
2. Materials and methods
2.1. Antibodies and reagents
Anti-PARP, anti-cleaved caspase 3 (Asp175), anti-phospho-P70S6K
(Thr389), anti-P70S6K, anti-phospho-S6 (Ser235/Ser236), anti-S6,
anti-CHOP, anti-phospho-PERK (Thr980), anti-PERK, anti-phospho-Akt
(Thr308), anti-phospho-Akt (Ser473), anti-phospho-AMPK (Thr172),
anti-AMPK, anti-phospho-Raptor (Ser792), anti-Raptor, anti-Rictor,
anti-mTOR, anti-p18 and anti-RagC antibodies were purchased from
Cell Signaling Technology (Beverly, MA, USA). Anti-LAMP2 antibody
was purchased from Abcam (Cambridge, UK). Anti-Akt antibody was
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-beta-actin
antibody, rapamycin and insulin were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Alexa 488-conjugated anti-rabbit IgG, Alexa 594-
conjugated anti-rat IgG, Alexa 594-conjugated anti-mouse IgG and
BODIPY C-16 were obtained from Molecular Probes (Eugene, OR,
USA). 4,6-Diamidino-2-phenylindole (DAPI) was purchased from
Dojindo Molecular Technologies (Kumamoto, Japan).
Lipid-containing media were prepared by conjugation of FFAs with
FFA-free bovine serum albumin. Bovine serum albumin (BSA; fattyacid free, fraction V) was obtained from Nacalai Tesque (Kyoto, Japan).
Brieﬂy, sodium palmitate (Sigma, St. Louis, MO, USA), oleic acid
(Sigma) and eicosapentaenoic acid (Cayman Chemical, Ann Arbor, MI,
USA) were dissolved in 50% ethanol and mixed vigorously with 12.5%
FFA-free BSA in phosphate-buffered saline (PBS).
2.2. Cell culture
Conditionally immortalized mouse podocyte cell lines were
established by Peter Mundel (Mount Sinai School of Medicine) [41].
Cells were cultured at 33 °C in RPMI-1640 medium supplemented
with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 μg/ml strepto-
mycin and 10 U/ml recombinant mouse γ-interferon (Cell Sciences,
Canton, MA, USA). To induce differentiation, podocytes were cultured
at 37 °C without γ-interferon (growth restrictive conditions) in the
samemedium for at least 7 days. Differentiated cellswere starvedby in-
cubation with FCS-free RPMI-1640 medium for 24 h, followed by stim-
ulation with 150 μM palmitate, 150 μM oleate or 50 μM EPA for 9 h.
For rapamycin treatment, cells were co-incubated with 0.5 ng/ml
rapamycin and palmitate. For experiments of amino acid depletion,
after serum starvation for 20 h, cells were washed with PBS twice and
incubated with Krebs–Ringer buffer (119.0 mM NaCl, 2.5 mM KCl,
1.3 mM MgCl2, 1.0 mM NaH2PO4, 2.5 mM CaCl2, 20.0 mM HEPES, and
5.5 mM D-glucose) for 2 h, followed by exposure to palmitate or a mix-
ture of amino acids as indicated for 6 h. The concentration of each amino
acid was (in mg/l): L-Arg, 84; L-Cys, 48; L-Glu, 584; L-His, 42; L-Ile, 105;
L-Leu, 105; L-Lys, 146; L-Met, 30; L-Phe, 66; L-Thr, 95; L-Trp, 16; L-Tyr, 72;
L-Val, 94 (Sigma, St. Louis, MO, USA) [42].
Human embryonic kidney cell line 293 (HEK293) cellswere cultured
as described [43]. Brieﬂy, cells were cultured in DMEM containing 10%
FCS, 100 U/ml penicillin and 100 μg/ml streptomycin at 37 °C and 5%
CO2 thermostat. Subconﬂuent cells were starved by incubation with
0.2% FCS DMEM for 12 h, followed by stimulation with 150 μM palmi-
tate, 150 μM oleate or 50 μM EPA for 9 h. For rapamycin treatment,
cells were co-incubated with 0.5 ng/ml rapamycin and palmitate.
2.3. Transfection with plasmids and siRNA
The plasmids for overexpression of Flag-RagA(TN), Flag-RagB(TN),
Myc-RagC and Myc-4E-BP1-4A were as described previously [44,45].
ON-TARGETplus smart pool siRNA for Raptor, Rictor and CHOP were
from Dharmacon (Lafayette, CO, USA). One-hundred picomole of
siRNA or control siRNA (non-targeting siRNA; Dharmacon) was
transfected into 1.6 × 106 podocytes using a Nucleofector Kit V accord-
ing to the manufacturer's guidelines (Amaxa Biosystems, Gaithersburg,
MD, USA). Brieﬂy, podocytes were suspended in 100 μl of Nucleofector
solution provided with the Amaxa transfection reagent with 3 μg of
plasmid DNA or 100 pmol of siRNA. Transfection was performed by
electroporation using the T-20 program of the Amaxa electroporator.
Transfected cells were incubated in RPMI medium containing 10% FCS
for 48 h prior to serum starvation. ON-TARGETplus smart pool siRNA re-
agent was a mix of four different siRNAs for each gene. Sequences of
siRNA were: for siRNA for CHOP: 5′-CAACAGAGGUCACACGCAC-3′, 5′-
GCACCAAGCAUGAACAGUG-3′, 5′-GAGCAAGGAAGAACUAGGA-3′, and
5′-GAAACAGAGUGGUCAGUGC-3′; for siRNA for Raptor: 5′-UAGAGG
UAGCUGCGAUUAA-3′, 5′-AUACUGACCGGGAGACGAA-3′, 5′-AGAAUG
AAGGAUCGGAUGA-3′, and 5′-CUGAGGAACACUCGAGUCA-3′; and for
siRNA for Rictor: 5′-CUUAGAAGAUCUCGUGAAA-3′, 5′-AUGUAGAAUU
AGAGCGAAU-3′, 5′-CAUUAAUUGCGGUUGGAAA-3′, and 5′-CGAUAU
UGGCCAUAGUGAA-3′.
2.4. Western blot analysis
Immunoblot analysis was performed as previously described [46].
Cell lysates in SDS sample buffers were electrophoresed and transferred
to polyvinylidene diﬂuoridemembranes (Immobilon,Millipore, Bedford,
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indicated antibodies. Horseradish peroxidase-conjugated anti-rabbit,
anti-mouse antibody (Amersham, Buckinghamshire, UK) and anti-goat
antibodies (Santa Cruz, CA, USA)were used as secondary antibodies. Im-
munoreactive bands were detected with an enhanced chemilumines-
cence detection system (PerkinElmer Life Science, Boston, MA, USA).
For cell fraction study, cytoplasmic andmembrane fractions were isolat-
ed using a subcellular protein fractionation kit (Thermo Scientiﬁc, Cin-
cinnati, OH, USA).
2.5. Immunoﬂuorescence staining
Cells cultured on chamber slides coated with collagen I were ﬁxed
with 4% paraformaldehyde. Fixed cells were rinsed three times with
PBS and permeabilized with 0.2% Triton X-100 in PBS for 10 min and
blocked with 2% BSA-TBS for 30min at room temperature. After rinsing
three timeswith TBS containing 0.05% Tween (TBS-T), sampleswere in-
cubated with primary antibodies in PBS for 3 h at room temperature,
rinsed three times with TBS-T, incubated with secondary antibodies
for 1 h at room temperature, washed twice with TBS-T, and rinsed
twice with PBS [47]. Antibodies were used at the following dilutions:
mTOR (1:400), LAMP2 (1:200), CHOP (1:1000), Alexa Fluor 488 anti-
rabbit IgG (1:500), Alexa Fluor 594 anti-rat IgG (1:500) and Alexa
Fluor 594 anti-mouse IgG (1:500). Before samples were mounted with
mounting medium, slides were stained using DAPI and chamber bor-
ders were removed. Immunoﬂuorescence staining was detected using
a ﬂuorescence microscope at original magniﬁcation with appropriate
ﬁlters (BX61, Olympus, Tokyo, Japan). The ratios of merged area to
LAMP2-positive area were digitally quantiﬁed using Image-Pro Plus
7.0 (Media Cybernetics, Bethesda, MD, USA).
2.6. TUNEL assay
Terminal deoxynucleotidyl transferase-mediated dUTP nick end-
labeling (TUNEL) staining was performed with an in situ apoptosis de-
tection kit (Takara-Bio Inc., Otsu, Japan). TUNEL-positive and -negative
cells were counted in ﬁve randomly selected areas of a cultured slide.
The results are expressed as a ratio of TUNEL-positive cells to total cell
number in each ﬁeld.
2.7. Fatty acid uptake assay
Cells plated on a 24-well plate were exposed to 50 μM of
ﬂuorescence-labeled palmitate (BODIPY C-16,Molecular Probes, Eugene,
OR, USA) with 150 μM of non-ﬂuorescence-labeled palmitate and co-
incubated with/without oleate or EPA for 30 min. After washing with
PBS, the uptake of ﬂuorescence-labeled palmitate was measured using
an Inﬁnite M200 microplate reader (Tecan, Männedorf, Switzerland).
2.8. Statistical analysis
Results are expressed asmean±SEM. Analysis of variancewith sub-
sequent Fisher's test was used to determine signiﬁcance of differences
in multiple comparisons. Pearson's correlation coefﬁcients were calcu-
lated to investigate the association among indicated parameters. A P-
value b 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Saturated and unsaturated fatty acids have opposite effects on
podocyte apoptosis
To examine the effect of each kind of FFA on podocyte apoptosis,
cultured podocytes were exposed to a saturated (palmitate), a
monounsaturated (oleate) and an ω− 3 polyunsaturated fatty acid
(eicosapentaenoic acid; EPA) for the indicated hours. Of the FFAs,palmitate induced apoptosis, as determined by cleavage of caspase 3
and poly(ADP-ribose) polymerase (PARP), after 9 h of stimulation
(Fig. 1A) in a concentration-dependent manner up to 150 μM (Fig. 1B
and C). Oleate and EPA did not induce apoptosis (Fig. 1A), and more
likely co-incubation with either oleate or EPA signiﬁcantly ameliorated
palmitate-induced cleavage of caspase 3 and PARP (Fig. 1D–F). The ef-
fect of each kind of FFA on apoptosis was validated by TUNEL assay. Pal-
mitate signiﬁcantly increased TUNEL-positive cell numbers, which was
signiﬁcantly ameliorated by co-incubation with oleate or EPA (Fig. 1G
and H).
We next examined the additive effects of other nutrient factors such
as the serum and/or glucose condition on palmitate-induced podocyte
apoptosis. Under glucose-containing conditions, palmitate induced apo-
ptosis regardless of glucose concentration and whether 10% FCS was
present (Fig. 1I and J). However, under glucose-free conditions, the
pro-apoptotic effect of palmitateweakened in 10% FCS-containing condi-
tions, and more likely rescued podocytes from nutrient-depletion-
induced apoptosis in FCS-free conditions (Fig. 1I and J). These results
suggest that palmitate is an essential energy source in glucose-free con-
ditions for cell survival, whereas palmitate becomes toxic and induces
apoptosis when in co-existence with other nutrient factors including
glucose.
3.2. Palmitate induced podocyte apoptosis via activation of mTORC1
signaling
To rule out the possibility that oleate and EPA interfered with palmi-
tate uptake into cells, we analyzed the effects of oleate and EPA on the
uptake of palmitate with ﬂuorescence-labeled palmitate. Both oleate
and EPA had no effect on palmitate uptake (Fig. 2A), suggesting that
both inhibited palmitate-induced apoptosis via the alteration of some
intracellular process.
We next tested the relationship between palmitate-induced apopto-
sis and mTORC1 signaling, as hyperactivation of mTORC1 has recently
been suggested to be a causal factor of podocyte dysfunction in diabetic
nephropathy [33,34]. Palmitate increased phosphorylation of P70S6KT389
and S6S235/236, downstream substrates of the mTORC1 signal, within the
ﬁrst 5min of exposure. This phosphorylation signiﬁcantly increased after
30min of palmitate stimulation andwas sustained for 9 h (Fig. 2B and C).
Thus, in a similar way to insulin and amino acids, palmitate was able to
begin to activate mTORC1 within a few minutes. Furthermore, co-
incubation with either oleate or EPA inhibited palmitate-induced phos-
phorylation of P70S6KT389 and S6S235/236 (Fig. 2D and E), suggesting
that both diminished palmitate-induced mTORC1 activation.
Rapamycin, a speciﬁc pharmacological inhibitor of mTORC1, de-
creased phosphorylation of P70S6KT389 and S6S235/236, and signiﬁcantly
diminished palmitate-induced podocyte apoptosis in a dose-dependent
manner (Fig. 2F and G). The anti-apoptotic effect of rapamycinwas con-
ﬁrmed by TUNEL staining (Fig. 2H).
To further conﬁrm the role ofmTORC1 in palmitate-induced apopto-
sis, we employed RNA interference to knockdown Raptor, an essential
component of mTORC1. Transfection with siRNA for Raptor inhibited
palmitate-induced phosphorylation of P70S6KT389 and S6S235/236 and
apoptosis, as determined by cleavage of PARP and caspase 3, and
TUNEL staining (Fig. 2I–K). To rule out the involvement of mTORC2 on
palmitate-induced podocyte apoptosis [48], we employed RNA interfer-
ence to knockdown Rictor, an essential component of mTORC2. Knock-
down of Rictor had no effect on palmitate-induced apoptosis (Fig. 2L),
suggesting that palmitate-induced podocyte apoptosis and the anti-
apoptotic effect of rapamycin were dependent on the mTORC1 signal.
To determine whether the pro-apoptotic function of mTORC1 was
speciﬁc to palmitate, we examined the relationship between apoptosis
andmTORC1 in cultured podocytes stimulatedwith insulin, a potent ac-
tivator of mTORC1 signaling. Unlike palmitate, insulin did not induce
apoptosis, although it did increase phosphorylation of P70S6KT389 and
S6S235/236 (Fig. 2M). Neither oleate nor EPA altered insulin-induced
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suggest that FFA-mediated, but not insulin-mediated, alteration of
mTORC1 activity is associated with cell apoptosis.
3.3. Palmitate induced endoplasmic reticulum stress-triggered apoptosis
via mTORC1 in podocytes
We investigated the downstream mechanisms of mTORC1-
dependent apoptosis in cultured podocytes stimulated with palmitate,Fig. 2. Palmitate induced podocyte apoptosis via activation of mTORC1 signaling. (A) Uptake of
ﬂuorescence-labeled palmitate with 150 μM of non-ﬂuorescence-labeled palmitate co-incubate
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OLE, oleate; EPA, eicosapentaenoic acid; TUNEL, terminal deoxynucleotidyl transferase-mediatwith a focus on endoplasmic reticulum (ER) stress, since it is suggested
to be related tomTORC1-dependent cell dysfunction and apoptosis [49].
Palmitate induced phosphorylation of PKR-like kinase (PERK) and
overexpression of C/EBP homologous protein (CHOP), a potent pro-
apoptotic transcription factor associated with ER stress [50], in a time-
dependent manner (Fig. 3A). We also conﬁrmed that both oleate and
EPA inhibited palmitate-induced phosphorylation of PERKT980 and over-
expression of CHOP (Fig. 3B–D). Nuclear overexpression of CHOP was
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r (Si-Rictor). (M) Cleavage of PARP, caspase 3, β-actin, phosphorylated P70S6KThr389,
dicated hours. (N) Phosphorylated P70S6KThr389, P70S6K, phosphorylated S6S235/236 and
data are expressed as mean ± SEM. PARP, poly(ADP-ribose) polymerase; PAL, palmitate;
ed dUTP nick end-labeling; Rapa, rapamycin; Si-Rap, Si-Raptor; NS, not signiﬁcant.
1101M. Yasuda et al. / Biochimica et Biophysica Acta 1842 (2014) 1097–1108related CHOP activationwas involved in palmitate-induced podocyte ap-
optosis, we employed RNA interference to knockdown CHOP. Knock-
down of CHOP signiﬁcantly ameliorated palmitate-induced cleavage of
PARP and caspase 3, and increased the number of TUNEL-positive cells
(Fig. 3F–H). These results suggest that ER stress was involved in
mTORC1-dependent apoptosis in cultured podocytes exposed to
palmitate.B
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dependent increases in ER stress and subsequent apoptosis in podocytes
stimulated with palmitate.
3.4. Palmitate activates mTORC1 by enhancing translocation of mTORC1
onto lysosomal membranes
With regard to themain regulatorymechanisms ofmTORC1 activity,
it has been reported that mTORC1 activity is upregulated by insulin-
induced activation of Akt and translocation of mTORC1 onto lysosomal
membranes mediated by some nutrient factors such as amino acids,
glucose, and glutaminolysis [25–29], and is suppressed by AMPK-
dependent phosphorylation of RaptorS792 (Fig. 4A) [24]. We thereforeinvestigated whether these upstream regulatory signals were involved
in the mechanism underlying palmitate-induced activation of mTORC1.
In Fig. 4B, the representative ﬁgure from the short exposure time
shows that insulin stimulation as a positive control to activate Akt was
able to induce maximal phosphorylation of AktT308 and AktS473 and
that the podocyte cell line had a very low basal level of Akt activity
under FCS-free conditions. The representative ﬁgure from the long ex-
posure time visualizes the basal levels of Akt in the cultured podocytes,
which were not altered by palmitate stimulation. In addition, we found
that palmitate did not alter phosphorylation of AMPKT172 and Rap-
torS792 (Fig. 4B), suggesting that the upstream signals are not involved
in palmitate-induced mTORC1 activation in podocytes. To investigate
whether amino acids were required for palmitate-induced mTORC1
1103M. Yasuda et al. / Biochimica et Biophysica Acta 1842 (2014) 1097–1108activation, we examined palmitate-induced mTORC1 activation in
podocytes cultured in Krebs–Ringer buffer not containing any amino
acids. Palmitate signiﬁcantly increased phosphorylation of P70S6KT389
and S6S235/236 even in Krebs–Ringer buffer such as amino acids (Fig. 4C).
These observations led us to hypothesize that palmitate stimulation
can recruit mTORC1 onto the lysosomal surface like other nutrients
(Fig. 4A). To investigate this hypothesis, we performed a double immu-
noﬂuorescence study using antibodies for mTOR and lysosome-
associated membrane protein-2 (LAMP2) [47], a protein localized on
the lysosomal membranes. In podocytes cultured in Krebs–Ringer buff-
er without any amino acid and palmitate, the green ﬂuorescent signals
of mTOR were diffusely distributed in the cytosol and little merged
with the red ﬂuorescent signals of LAMP2 (Fig. 4D). Both amino acids
as a positive control and palmitate increased the co-localization of
mTOR with LAMP2 around the nucleus (Fig. 4D and F). Since Roswell
Park Memorial Institute (RPMI) medium contains amino acids, mTOR
was partly coupled with the lysosomal membranes as deﬁned by the
LAMP2-positive component even under unstimulated conditions
(Fig. 4E). In podocytes cultured in RPMI medium, palmitate, but not in-
sulin, further accelerated the translocation of mTOR onto lysosomal
membranes (Fig. 4E and F). This ﬁnding was conﬁrmed by cell fraction
study. Protein expression levels of Raptor and mTOR increased in the
membrane fraction containing the lysosomal membrane, characterized
by LAMP2 expression in podocytes cultured in Krebs–Ringer buffer
stimulated with amino acids and palmitate (Fig. 4G). These results sug-
gest that palmitate enhances translocation of mTOR onto the lysosomal
membranes, leading to mTORC1 activation.
Since mTORC1 is recruited onto lysosomal membranes in a Rag–
Ragulator complex-dependent manner (Fig. 4A) [25–27], we analyzed
palmitate-induced apoptosis in cells transfected with the dominant-
negative form of RagA or RagB together with co-transfection of RagC
to examine the relationship between mTORC1 translocation and
palmitate-induced apoptosis in cultured podocytes. Co-transfection
with either the dominant-negative form of RagA or RagB with RagC di-
minished palmitate-induced overexpression of CHOP and cleavage of
caspase 3 (Fig. 4H and I), suggesting that palmitate-induced recruit-
ment of mTORC1 onto the lysosomal surface was essential for
palmitate-induced apoptosis in cultured podocytes.
Ragulator is the trimeric p14, p18, and MP1 protein complex
(Fig. 4A). Since palmitoylation of p18 is essential for anchoring the
Rag–Ragulator complex to the lysosomal surface [51], we hypothesized
that palmitate increased palmitoylation of p18, leading to an accumula-
tion of the Rag–Ragulator complex on lysosomal membranes. However,
palmitate did not alter localization of either p18 or RagC proteins
(Fig. 4J).
3.5. Oleate and EPA inhibit palmitate-induced translocation of mTOR onto
lysosomal membranes
We investigatedwhether unsaturated fatty acids affected palmitate-
induced translocation of mTOR onto lysosomal membranes. Both oleate
and EPA inhibited palmitate-induced translocation of mTOR onto lyso-
somalmembranes (Fig. 5A and B). In contrast, oleate and EPAdid not af-
fect amino acid-induced mTOR translocation onto lysosomal
membranes in podocytes cultured in Krebs–Ringer buffer (Fig. 5C and
D). Nor did oleate or EPA alter the expression patterns of either p18 or
RagC (Fig. 5E–H). In addition to the ﬁnding that both oleate and EPA
did not inhibit insulin-induced mTORC1 activation (Fig. 2N), these re-
sults suggest that unsaturated FFAs can antagonize palmitate-induced
mTORC1 translocation, but they do not have a uniquemechanism to in-
hibit mTORC1 activity.
3.6. FFAs regulate the pro-apoptotic function of mTORC1 in HEK293 cells
To investigate whether the FFA-related pro-apoptotic function of
mTORC1 was speciﬁc to podocytes, we conducted similar experimentsto those above using cultured human embryonic kidney cell line 293
(HEK293) cells. Like the podocyte study, palmitate increased cleavage
of PARP and caspase 3, and increased phosphorylation of P70S6KT389
and S6S235/236 and expression of CHOP (Fig. 6A). We also conﬁrmed ap-
optosis by TUNEL assay, and ER stress by immunoﬂuorescence study
using an antibody for CHOP (Fig. 6B and C). These actions were all re-
versed by co-incubationwith either oleate or EPA (Fig. 6A–C), and treat-
ment with rapamycin (Fig. 6D–F). Furthermore, both oleate and EPA
inhibited palmitate-induced enhancement of mTOR translocation onto
lysosomal membranes in HEK293 cells (Fig. 6G).
4. Discussion
The results of this study suggest that palmitate, a saturated FFA, is a
potent nutrient that can induce ER stress-related apoptosis by activating
the pro-apoptotic function of mTORC1 in cultured podocytes and
HEK293 cells. Saturated FFAs activate mTORC1 signaling by enhancing
mTORC1 translocation onto lysosomal membranes. In contrast, unsatu-
rated FFAs can antagonize palmitate-induced hyperactivation of
mTORC1 and ER stress-related apoptosis by inhibitingmTORC1 translo-
cation (Fig. 7). These results provide novel information on the role of
FFAs in mTORC1-dependent cell biology and podocyte apoptosis in dia-
betic nephropathy.
We suggest that saturated FFA is a novel nutritional activator of
mTORC1. There are at least ﬁve major activators of mTORC1, including
insulin, stress, glucose, oxygen and amino acids, controllingmany intra-
cellular processes, such as protein and lipid synthesis, cell growth and
proliferation, glycolysis, and autophagy [19–21]. Hyperglycemia has
been suggested to be a major player in the activation of the mTORC1
pathway in various cells under diabetic conditions, leading to diabetic
vascular complications [52,53]. Insufﬁciency of insulin action in diabetes
causes the elevation of serumFFA levels aswell as hyperglycemia. Based
on ourﬁndings, an increased FFA level is also likely to be associatedwith
diabetes-related mTORC1 activation leading to diabetic complications.
Saturated FFA induced apoptosis via hyperactivation of mTORC1 but
not of mTORC2. Interestingly, there seems to be distinct biological roles
of mTORC1 in cells treated with saturated FFAs and other stimuli. The
results of the present study show that palmitate-induced mTORC1 acti-
vation leads to apoptosis, whereas insulin does not, and that unsaturat-
ed FFAs antagonized palmitate-induced, but not insulin-induced,
mTORC1 activation. These results suggest that FFAs have unique roles
in mTORC1-dependent cell biology, particularly in association with
cell apoptosis. Furthermore, the ﬁndings were reproduced in cultured
HEK293 cells, indicating that palmitate-induced mTORC1 activation
and subsequent apoptosis are not speciﬁc to podocytes. This ﬁnding
provides additional information about the physiological biology of
mTORC1 in cell death.
mTORC1 activity is regulated by two distinctmechanisms: upstream
signal transduction; and translocation onto lysosomal membranes
(Fig. 4A) [20]. This study investigated which mechanism was involved
in palmitate-inducedmTORC1 activation. Our ﬁndings suggest that pal-
mitate did not alter Akt- and AMPK-dependent regulation of mTORC1
activity, suggesting that upstream signals are not involved in
palmitate-induced mTORC1 activation.
Of the original mTORC1 activators mentioned above, amino acids,
glutaminolysis and glucose have been reported to be able to activate
translocation of mTORC1 onto lysosomal membranes where Rheb is lo-
calized [25–29]. Palmitate-inducedmTORC1 activation was observed to
occur within minutes, suggesting that palmitate directly activates
mTORC1, like amino acid-mediated activation; although we have not
completely ruled out the possibility that mTORC1 was activated indi-
rectly via some intracellular intermediate process such as increasing
de novo synthesis of glucose or amino acid. This is the ﬁrst study to re-
port that palmitate is an additional nutrient that can translocate
mTORC1 onto lysosomal membranes and this translocation is essential
for palmitate-induced CHOP induction and apoptosis.
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Fig. 5.Oleate and EPA inhibit palmitate-induced translocation ofmTOR onto lysosomalmembranes. (A) Representative photomicrographs showing co-immunostaining formTOR (green) and
LAMP2 (red) in cultured podocytes stimulated with palmitate with/without oleate or EPA in RPMImedium. Original magniﬁcation: ×1000. (B) The ratios of merged area (yellow) to LAMP2-
positive area (yellow and red) in each group (n= 10). (C) Co-immunostaining for mTOR (green) and LAMP2 (red) in cultured podocytes stimulatedwith amino acids with/without oleate or
EPA in Krebs–Ringer buffer. Originalmagniﬁcation: ×1000. (D) The ratios ofmerged area (yellow) to LAMP2-positive area (yellowand red) in each group (n=10). (E) Co-immunostaining for
p18 (green) and LAMP2 (red) in cultured podocytes stimulatedwith palmitate and co-incubatedwith oleate or EPA in RPMImedium. Original magniﬁcation: ×1000. (F) The ratios of merged
area (yellow) to LAMP2-positive area (yellowand red) in each group (n=10). (G) Co-immunostaining for RagC (green) and LAMP2 (red) in cultured podocytes stimulatedwith palmitate and
co-incubatedwith oleate or EPA in RPMImedium. Original magniﬁcation: ×1000. (H) The ratios of merged area (yellow) to LAMP2-positive area (yellow and red) in each group (n=10). All
data are expressed as mean ± SEM. LAMP2, lysosome-associated membrane protein 2; PAL, palmitate; OLE, oleate; EPA, eicosapentaenoic acid; NS, not signiﬁcant.
Fig. 4. Palmitate activatesmTORC1by enhancing translocation ofmTORonto lysosomalmembranes. (A) Schematic representation ofmTORC1 regulation. (B) Representative immunoblots
of phosphorylated AktThr308 from short and long exposure times, phosphorylated AktSer473 from short and long exposure times, Akt, phosphorylated AMPKThr172, AMPK, phosphorylated
RaptorSer792 and Raptor in cultured podocytes exposed to palmitate for the indicated hours in RPMI medium. (C) Phosphorylated P70S6KThr389, P70S6K, phosphorylated S6S235/236 and S6
in cultured podocytes exposed to palmitate in Krebs–Ringer buffer for the indicated hours. Quantitative analysis of the ratios of phosphorylated P70S6KThr389 to P70S6K and phosphory-
lated S6S235/236 to S6 (n= 6). (D) Representative photomicrographs showing co-immunostaining for mTOR (green) and LAMP2 (red) in cultured podocytes stimulatedwith amino acids
or palmitate for 6 h with 2 h of pre-incubation in Krebs–Ringer buffer. Original magniﬁcation: ×1000. (E) Co-immunostaining for mTOR (green) and LAMP2 (red) in cultured podocytes
stimulated with insulin or palmitate in FCS-free RPMI medium. Original magniﬁcation: ×1000. (F) The ratios of merged area (yellow) to LAMP2-positive area (yellow and red) in each
group (n = 10). (G) Raptor, mTOR and LAMP2 in cytoplasmic and membrane fractions of cultured podocytes with amino acids or palmitate for 6 h with 2 h of pre-incubation in
Krebs–Ringer buffer. (H) Phosphorylated S6S235/236, S6, CHOP, cleavage of caspase 3 and β-actin in palmitate-stimulated podocytes transfected with dominant-negative forms of RagA
or RagB with co-transfection with RagC. (I) Representative photomicrographs showing TUNEL staining of cultured podocytes transfected with dominant-negative forms of RagA or
RagB with co-transfection with RagC exposed to palmitate for 9 h. Original magniﬁcation: ×200. Percentage of TUNEL-positive cell numbers from these three groups (n = 5). (J) Co-
immunostaining for p18 (green), RagC (green) and LAMP2 (red) in cultured podocytes stimulated with palmitate in Krebs–Ringer buffer. Original magniﬁcation: ×1000. All data are
expressed asmean± SEM. Akt, serine/threonine kinase; AMPK, AMP-activated protein kinase; PARP, poly(ADP-ribose) polymerase; Krebs–Ringer buffer (KRB), amino acid freemedium;
RPMImedium, standardmedium; PAL, palmitate; AA, amino acids; LAMP2, lysosome-associatedmembrane protein 2; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick
end-labeling; NS, not signiﬁcant.
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Fig. 6. Saturated andunsaturated fatty acids have opposite effects onmTORC1-dependent apoptosis inHEK293 cells. (A) Representative immunoblots showing cleavageof PARP, caspase 3,
phosphorylated P70S6KThr389, P70S6K, phosphorylated S6S235/236, S6 and CHOP inHEK293 cells exposed to palmitate and co-incubatedwith oleate or EPA; β-actinwas used as the loading
control. (B) Representative photomicrographs showing TUNEL staining of cultured HEK293 cells stimulated with palmitate with/without oleate or EPA. Original magniﬁcation: ×200.
Percentage of TUNEL-positive cell numbers from each group (n = 5). (C) Representative photomicrographs showing CHOP staining of cultured HEK293 cells stimulated with palmitate
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(G) Representative photomicrographs showing co-immunostaining for mTOR (green) and LAMP2 (red) in HEK293 cells stimulated with palmitate with/without oleate or EPA in FCS-
free DMEM. Original magniﬁcation: ×1000. All data are expressed as mean ± SEM. PARP, poly(ADP-ribose) polymerase; CHOP, C/EBP homologous protein; PAL, palmitate; OLE, oleate;
EPA, eicosapentaenoic acid; Rapa, rapamycin; LAMP2, lysosome-associated membrane protein 2; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling; NS,
not signiﬁcant.
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mTORC1 translocation. Unfortunately, our hypothesis that palmitate in-
creases the recruitment of the Rag–Ragulator complex to the lysosomal
surface by increasing p18 palmitoylation was not supported by the re-
sults. Similar to amino acid- or glucose-mediated translocation, it still
remains to be discovered how palmitate activates the Rag–Ragulator
complex leading to mTORC1 translocation. Nonetheless, it is of interest
to examine whether there are any differences between the molecularmechanisms of amino acid-/glucose- and FFA-mediated translocation
of mTORC1.
This study suggests that palmitate-induced apoptosis is mediated by
a mTORC1–ER stress pathway. Evidence of crosstalk between mTORC1
and ER stress has recently emerged, as growing research suggests that
mTORC1-related ER stress is involved in the pathogenesis of various
diabetes-related organ dysfunctions [34,49,54]. This study has provided
an additional pathological role of the crosstalk in diabetes-related
LysosomemTORC1 mTORC1
ER stress
(CHOP induction)
Apoptosis
Saturated
fatty acids
Translocation
Unsaturated
fatty acids
Fig. 7. Schematic representation of differential roles of saturated and unsaturated FFAs in
mTORC1 activation and subsequent apoptosis. Saturated fatty acids activate mTORC1 by
enhancing translocation of mTORC1 onto lysosomal membranes, leading to ER stress-
related apoptosis. In contrast, unsaturated FFAs can antagonize saturated fatty acid-
induced apoptosis by inhibiting translocation of mTORC1 onto the lysosomal surface.
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of the crosstalk in cell apoptosis, although the details have not been
fully elucidated [49,55,56]. In this study, we observed that 4E-BP1-
dependent inhibition of translation amelioratedpalmitate-induced apo-
ptosis. This ﬁnding suggests that mTORC1-dependent enhancement of
translation may be involved in palmitate-induced ER stress and subse-
quent apoptosis in podocytes.
Inhibition of mTORC1 hyperactivation in podocytes is thought to be
a potent therapeutic target for diabetic nephropathy [35–37]. However,
strong inhibition ofmTORC1often causes proteinuria [38,39]. It is there-
fore desirable that the details and speciﬁc molecular mechanisms of
diabetes-related hyperactivation of mTORC1 be elucidated. Insulin-,
amino acid- and glucose-inducedmTORC1 activationmay play a funda-
mental role in podocyte biology. In contrast, based on our results, of the
several nutritional activators of mTORC1, saturated FFAs could be asso-
ciatedwith diabetes-related hyperactivation ofmTORC1 in podocytes. If
only saturated FFAs, but not other mTORC1 activators, play a patholog-
ical role in podocyte apoptosis in diabetic nephropathy, identiﬁcation of
detailed molecular mechanisms underlying saturated FFA-induced
mTORC1 activation or saturated FFA-speciﬁc downstream apoptotic
pathways related to mTORC1 may lead to novel and safer therapies to
prevent podocyte apoptosis in diabetic nephropathy.
In this study, palmitate induced apoptosis in glucose-containing
conditions and prevented nutrient-depletion-induced apoptosis in
podocytes cultured in FCS-free mediumwithout glucose. The reciprocal
effect of palmitate on apoptosis is very interesting with regard to the
pathogenesis of diabetic complications. A high plasma FFA concentra-
tion with the high glucose condition is a unique pathological condition
only seen in the diabetic condition. Our results suggest that palmitate
would be safe under nutrient-depleted conditions such as starvation
since it is physiologically required for maintaining energy production,
whereas it can become a toxic nutrient factor inducing apoptosis
under nutrient- and glucose-rich conditions such as diabetes and an
insulin-resistant state.
Our in vitro study suggests the possibility that alteration of serum
FFA composition may be a pathogenesis of podocyte apoptosis in pa-
tientswith diabetes, and supports theﬁndings frommore recent reports
[57]. Furthermore, recent human studies have revealed that the concen-
trations of saturated fatty acids in overweight people or patients with
type 2 diabetes are signiﬁcantly higher than those in people of normal
weight or non-diabetic people [13–15]. Our ﬁndings that saturated
and unsaturated FFAs show opposite effects onmTORC1-dependent ap-
optosis in podocytes suggest that an altered serum FFA proﬁle isassociated with hyperactivation of mTORC1 and subsequent podocyte
apoptosis in patients with type 2 diabetes. These results propose that
some pharmacological or dietary intervention aimed at correcting the
serum FFA proﬁle may be useful for preventing podocyte apoptosis.
However, further clinical studies are required.
5. Conclusion
Our data suggest that saturated and unsaturated FFAs show opposite
effects on podocyte apoptosis, and that mTORC1 is a novel inducer of
saturated FFA-related cell apoptosis. Ameliorating saturated FFA-
mediated apoptosis withmTORC1 hyperactivationmay be a new thera-
peutic target to protect podocytes in diabetic nephropathy.
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